Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 21st Preview)
-
Novartis pays $2B upfront for Synnovation PI3Kα program
Novartis agreed to acquire Synnovation Therapeutics’ PI3Kα program, paying $2 billion in cash up front to buy Pikavation Therapeutics and its mutation‑selective candidate SNV4818. The deal gives Novartis a next‑generation PI3Kα inhibitor designed to selectively target mutant PI3Kα and avoid wild‑type inhibition that drives toxicity. Synnovation and Novartis said SNV4818 aims to improve tolerability over existing agents such as Piqray by enabling sustained dosing and combination use; the asset is in early clinical testing with a primary completion date in 2027. The transaction reflects big‑pharma appetite for differentiated kinase inhibitors that can defend established franchises and move into earlier lines of care.
-
AI drugmaker Earendil raises $787M to scale biologics pipeline
Earendil Labs secured $787 million in private financing to accelerate a broad AI‑driven biologics pipeline and expand R&D capacity across the U.S. and China. Lead investors included Dimension and Luminous Ventures, with strategic participation from Sanofi; the funding is intended to advance multiple programs toward the clinic while building an R&D organization at scale. Earendil says its platform has produced more than 40 programs, with several bispecifics, T‑cell engagers and ADCs in development and an IBD candidate ready for Phase 2. The round positions the company for larger clinical investments and a potential Hong Kong IPO while deepening partnerships with big pharma.
-
FDA clears high‑dose Wegovy under commissioner’s voucher
The FDA approved a 7.2 mg high‑dose formulation of Novo Nordisk’s Wegovy, granting a faster review under the commissioner’s voucher program that cut the evaluation to roughly two months. Novo received the voucher after a pricing agreement with the White House; the agency completed review 54 days after the filing. Novo positions the higher dose as a clinical option to regain share versus Lilly’s competing agents; trial data showed stronger weight loss at the higher dose. The approval underscores how regulatory acceleration mechanisms and pricing deals can compress timelines for high‑profile obesity medicines.
-
Abbott closes $23B Exact Sciences acquisition — expands diagnostics
Abbott completed its $23 billion acquisition of Exact Sciences, adding Cologuard, Oncotype DX and other cancer‑screening and molecular diagnostics assets to its portfolio. Abbott expects the deal to add roughly $3 billion of incremental sales in 2026 and to strengthen its presence in cancer screening and diagnostics. Abbott said the purchase accelerates its strategic push into one of healthcare’s fastest‑growing segments and expands its capabilities across molecular and population screening. Management highlighted expected near‑term revenue growth and integration plans while noting the transaction will modestly dilute adjusted EPS in the short term.
-
Tumor whole‑genome sequencing informs care in 41% of real‑world cases
A real‑world study of 888 solid‑tumor patients published in Nature Medicine found routine paired tumor‑normal whole‑genome sequencing (WGS) delivered actionable results with clinical consequences in 41% of cases. WGS succeeded in 89% of tests with a median turnaround of six working days and identified potentially actionable biomarkers in 73% of patients. The paper reports biomarker‑informed therapies were started in a substantial subset and were associated with longer median overall survival. The findings supply empirical support for broader WGS adoption in comprehensive cancer centers and for integrating tumor‑agnostic genomic testing into routine care pathways.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.